Global Chemotherapy Induced Peripheral Neuropathy Treatment Supply, Demand and Key Producers, 2024-2030
Page: 131
Published Date: 09 Feb 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is expected to reach $ 2613.1 million by 2030, rising at a market growth of 6.1% CAGR during the forecast period (2024-2030).
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
This report studies the global Chemotherapy Induced Peripheral Neuropathy Treatment production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Chemotherapy Induced Peripheral Neuropathy Treatment, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chemotherapy Induced Peripheral Neuropathy Treatment that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Chemotherapy Induced Peripheral Neuropathy Treatment total production and demand, 2019-2030, (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment total production value, 2019-2030, (USD Million)
Global Chemotherapy Induced Peripheral Neuropathy Treatment production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Chemotherapy Induced Peripheral Neuropathy Treatment domestic production, consumption, key domestic manufacturers and share
Global Chemotherapy Induced Peripheral Neuropathy Treatment production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).
This reports profiles key players in the global Chemotherapy Induced Peripheral Neuropathy Treatment market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc and DermaXon LLC, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chemotherapy Induced Peripheral Neuropathy Treatment market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation by Type
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Companies Profiled:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Key Questions Answered
1. How big is the global Chemotherapy Induced Peripheral Neuropathy Treatment market?
2. What is the demand of the global Chemotherapy Induced Peripheral Neuropathy Treatment market?
3. What is the year over year growth of the global Chemotherapy Induced Peripheral Neuropathy Treatment market?
4. What is the production and production value of the global Chemotherapy Induced Peripheral Neuropathy Treatment market?
5. Who are the key producers in the global Chemotherapy Induced Peripheral Neuropathy Treatment market?
Table of Contents
1 Supply Summary
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
1.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Supply & Forecast
1.2.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value (2019 & 2023 & 2030)
1.2.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030)
1.2.3 World Chemotherapy Induced Peripheral Neuropathy Treatment Pricing Trends (2019-2030)
1.3 World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region (Based on Production Site)
1.3.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Region (2019-2030)
1.3.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region (2019-2030)
1.3.3 World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Region (2019-2030)
1.3.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030)
1.3.5 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030)
1.3.6 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Major Market Trends
2.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Demand (2019-2030)
2.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Region
2.2.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Region (2019-2024)
2.2.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast by Region (2025-2030)
2.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030)
2.4 China Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030)
2.5 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030)
2.6 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030)
2.7 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030)
2.8 ASEAN Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030)
2.9 India Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030)
3.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Manufacturer (2019-2024)
3.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Manufacturer (2019-2024)
3.3 World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Manufacturer (2019-2024)
3.4 Chemotherapy Induced Peripheral Neuropathy Treatment Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Chemotherapy Induced Peripheral Neuropathy Treatment in 2023
3.5.3 Global Concentration Ratios (CR8) for Chemotherapy Induced Peripheral Neuropathy Treatment in 2023
3.6 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Overall Company Footprint Analysis
3.6.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Region Footprint
3.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Company Product Type Footprint
3.6.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4.1 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Comparison
4.1.1 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Comparison (2019 & 2023 & 2030)
4.1.2 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share Comparison (2019 & 2023 & 2030)
4.2 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Comparison
4.2.1 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share Comparison (2019 & 2023 & 2030)
4.3 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Comparison
4.3.1 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Comparison (2019 & 2023 & 2030)
4.3.2 United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share Comparison (2019 & 2023 & 2030)
4.4 United States Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers and Market Share, 2019-2024
4.4.1 United States Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value (2019-2024)
4.4.3 United States Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2024)
4.5 China Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers and Market Share
4.5.1 China Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value (2019-2024)
4.5.3 China Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2024)
4.6 Rest of World Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers and Market Share, 2019-2024
4.6.1 Rest of World Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value (2019-2024)
4.6.3 Rest of World Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2024)
5.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Calcium Channel α2-delta Ligands
5.2.2 Antidepressants
5.2.3 Opioids
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Type (2019-2030)
5.3.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Type (2019-2030)
5.3.3 World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Type (2019-2030)
6.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Platinum Agents
6.2.2 Taxanes
6.2.3 Vinca Alkaloids
6.2.4 Others
6.3 Market Segment by Application
6.3.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Application (2019-2030)
6.3.2 World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Application (2019-2030)
6.3.3 World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Application (2019-2030)
7.1 Aptinyx Inc
7.1.1 Aptinyx Inc Details
7.1.2 Aptinyx Inc Major Business
7.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.1.5 Aptinyx Inc Recent Developments/Updates
7.1.6 Aptinyx Inc Competitive Strengths & Weaknesses
7.2 Asahi Kasei Pharma Corp
7.2.1 Asahi Kasei Pharma Corp Details
7.2.2 Asahi Kasei Pharma Corp Major Business
7.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.2.5 Asahi Kasei Pharma Corp Recent Developments/Updates
7.2.6 Asahi Kasei Pharma Corp Competitive Strengths & Weaknesses
7.3 Regenacy Pharmaceuticals
7.3.1 Regenacy Pharmaceuticals Details
7.3.2 Regenacy Pharmaceuticals Major Business
7.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.3.5 Regenacy Pharmaceuticals Recent Developments/Updates
7.3.6 Regenacy Pharmaceuticals Competitive Strengths & Weaknesses
7.4 MAKScientific LLC
7.4.1 MAKScientific LLC Details
7.4.2 MAKScientific LLC Major Business
7.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.4.5 MAKScientific LLC Recent Developments/Updates
7.4.6 MAKScientific LLC Competitive Strengths & Weaknesses
7.5 Metys Pharmaceuticals AG
7.5.1 Metys Pharmaceuticals AG Details
7.5.2 Metys Pharmaceuticals AG Major Business
7.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.5.5 Metys Pharmaceuticals AG Recent Developments/Updates
7.5.6 Metys Pharmaceuticals AG Competitive Strengths & Weaknesses
7.6 Nemus Bioscience Inc
7.6.1 Nemus Bioscience Inc Details
7.6.2 Nemus Bioscience Inc Major Business
7.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.6.5 Nemus Bioscience Inc Recent Developments/Updates
7.6.6 Nemus Bioscience Inc Competitive Strengths & Weaknesses
7.7 PledPharma
7.7.1 PledPharma Details
7.7.2 PledPharma Major Business
7.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.7.5 PledPharma Recent Developments/Updates
7.7.6 PledPharma Competitive Strengths & Weaknesses
7.8 Sova Pharmaceuticals Inc
7.8.1 Sova Pharmaceuticals Inc Details
7.8.2 Sova Pharmaceuticals Inc Major Business
7.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.8.5 Sova Pharmaceuticals Inc Recent Developments/Updates
7.8.6 Sova Pharmaceuticals Inc Competitive Strengths & Weaknesses
7.9 DermaXon LLC
7.9.1 DermaXon LLC Details
7.9.2 DermaXon LLC Major Business
7.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.9.5 DermaXon LLC Recent Developments/Updates
7.9.6 DermaXon LLC Competitive Strengths & Weaknesses
7.10 Kineta Inc
7.10.1 Kineta Inc Details
7.10.2 Kineta Inc Major Business
7.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.10.5 Kineta Inc Recent Developments/Updates
7.10.6 Kineta Inc Competitive Strengths & Weaknesses
7.11 Krenitsky Pharmaceuticals Inc
7.11.1 Krenitsky Pharmaceuticals Inc Details
7.11.2 Krenitsky Pharmaceuticals Inc Major Business
7.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.11.5 Krenitsky Pharmaceuticals Inc Recent Developments/Updates
7.11.6 Krenitsky Pharmaceuticals Inc Competitive Strengths & Weaknesses
7.12 PeriphaGen
7.12.1 PeriphaGen Details
7.12.2 PeriphaGen Major Business
7.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.12.5 PeriphaGen Recent Developments/Updates
7.12.6 PeriphaGen Competitive Strengths & Weaknesses
7.13 Apexian Pharma
7.13.1 Apexian Pharma Details
7.13.2 Apexian Pharma Major Business
7.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.13.5 Apexian Pharma Recent Developments/Updates
7.13.6 Apexian Pharma Competitive Strengths & Weaknesses
7.14 WinSanTor
7.14.1 WinSanTor Details
7.14.2 WinSanTor Major Business
7.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
7.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.14.5 WinSanTor Recent Developments/Updates
7.14.6 WinSanTor Competitive Strengths & Weaknesses
8.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain
8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Upstream Analysis
8.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Core Raw Materials
8.2.2 Main Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Chemotherapy Induced Peripheral Neuropathy Treatment Production Mode
8.6 Chemotherapy Induced Peripheral Neuropathy Treatment Procurement Model
8.7 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Sales Model and Sales Channels
8.7.1 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Model
8.7.2 Chemotherapy Induced Peripheral Neuropathy Treatment Typical Customers
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Region (2019, 2023 and 2030) & (USD Million)
Table 2. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Region (2019-2024) & (USD Million)
Table 3. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Region (2025-2030) & (USD Million)
Table 4. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share by Region (2019-2024)
Table 5. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share by Region (2025-2030)
Table 6. World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region (2019-2024) & (K Units)
Table 7. World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region (2025-2030) & (K Units)
Table 8. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share by Region (2019-2024)
Table 9. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share by Region (2025-2030)
Table 10. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Region (2019-2024) & (US$/Unit)
Table 11. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Region (2025-2030) & (US$/Unit)
Table 12. Chemotherapy Induced Peripheral Neuropathy Treatment Major Market Trends
Table 13. World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
Table 14. World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Region (2019-2024) & (K Units)
Table 15. World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast by Region (2025-2030) & (K Units)
Table 16. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Manufacturer (2019-2024) & (USD Million)
Table 17. Production Value Market Share of Key Chemotherapy Induced Peripheral Neuropathy Treatment Producers in 2023
Table 18. World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Manufacturer (2019-2024) & (K Units)
Table 19. Production Market Share of Key Chemotherapy Induced Peripheral Neuropathy Treatment Producers in 2023
Table 20. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Evaluation Quadrant
Table 22. World Chemotherapy Induced Peripheral Neuropathy Treatment Industry Rank of Major Manufacturers, Based on Production Value in 2023
Table 23. Head Office and Chemotherapy Induced Peripheral Neuropathy Treatment Production Site of Key Manufacturer
Table 24. Chemotherapy Induced Peripheral Neuropathy Treatment Market: Company Product Type Footprint
Table 25. Chemotherapy Induced Peripheral Neuropathy Treatment Market: Company Product Application Footprint
Table 26. Chemotherapy Induced Peripheral Neuropathy Treatment Competitive Factors
Table 27. Chemotherapy Induced Peripheral Neuropathy Treatment New Entrant and Capacity Expansion Plans
Table 28. Chemotherapy Induced Peripheral Neuropathy Treatment Mergers & Acquisitions Activity
Table 29. United States VS China Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 30. United States VS China Chemotherapy Induced Peripheral Neuropathy Treatment Production Comparison, (2019 & 2023 & 2030) & (K Units)
Table 31. United States VS China Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
Table 32. United States Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value, (2019-2024) & (USD Million)
Table 34. United States Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share (2019-2024)
Table 35. United States Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2024) & (K Units)
Table 36. United States Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share (2019-2024)
Table 37. China Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value, (2019-2024) & (USD Million)
Table 39. China Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share (2019-2024)
Table 40. China Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2024) & (K Units)
Table 41. China Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share (2019-2024)
Table 42. Rest of World Based Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value, (2019-2024) & (USD Million)
Table 44. Rest of World Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share (2019-2024)
Table 45. Rest of World Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2024) & (K Units)
Table 46. Rest of World Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share (2019-2024)
Table 47. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Type, (USD Million), 2019 & 2023 & 2030
Table 48. World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Type (2019-2024) & (K Units)
Table 49. World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Type (2025-2030) & (K Units)
Table 50. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Type (2019-2024) & (USD Million)
Table 51. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Type (2025-2030) & (USD Million)
Table 52. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Type (2019-2024) & (US$/Unit)
Table 53. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Type (2025-2030) & (US$/Unit)
Table 54. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Application, (USD Million), 2019 & 2023 & 2030
Table 55. World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Application (2019-2024) & (K Units)
Table 56. World Chemotherapy Induced Peripheral Neuropathy Treatment Production by Application (2025-2030) & (K Units)
Table 57. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Application (2019-2024) & (USD Million)
Table 58. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Application (2025-2030) & (USD Million)
Table 59. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Application (2019-2024) & (US$/Unit)
Table 60. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Application (2025-2030) & (US$/Unit)
Table 61. Aptinyx Inc Basic Information, Manufacturing Base and Competitors
Table 62. Aptinyx Inc Major Business
Table 63. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 64. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 65. Aptinyx Inc Recent Developments/Updates
Table 66. Aptinyx Inc Competitive Strengths & Weaknesses
Table 67. Asahi Kasei Pharma Corp Basic Information, Manufacturing Base and Competitors
Table 68. Asahi Kasei Pharma Corp Major Business
Table 69. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 70. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 71. Asahi Kasei Pharma Corp Recent Developments/Updates
Table 72. Asahi Kasei Pharma Corp Competitive Strengths & Weaknesses
Table 73. Regenacy Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 74. Regenacy Pharmaceuticals Major Business
Table 75. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 76. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Regenacy Pharmaceuticals Recent Developments/Updates
Table 78. Regenacy Pharmaceuticals Competitive Strengths & Weaknesses
Table 79. MAKScientific LLC Basic Information, Manufacturing Base and Competitors
Table 80. MAKScientific LLC Major Business
Table 81. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 82. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 83. MAKScientific LLC Recent Developments/Updates
Table 84. MAKScientific LLC Competitive Strengths & Weaknesses
Table 85. Metys Pharmaceuticals AG Basic Information, Manufacturing Base and Competitors
Table 86. Metys Pharmaceuticals AG Major Business
Table 87. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 88. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Metys Pharmaceuticals AG Recent Developments/Updates
Table 90. Metys Pharmaceuticals AG Competitive Strengths & Weaknesses
Table 91. Nemus Bioscience Inc Basic Information, Manufacturing Base and Competitors
Table 92. Nemus Bioscience Inc Major Business
Table 93. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 94. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 95. Nemus Bioscience Inc Recent Developments/Updates
Table 96. Nemus Bioscience Inc Competitive Strengths & Weaknesses
Table 97. PledPharma Basic Information, Manufacturing Base and Competitors
Table 98. PledPharma Major Business
Table 99. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 100. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 101. PledPharma Recent Developments/Updates
Table 102. PledPharma Competitive Strengths & Weaknesses
Table 103. Sova Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 104. Sova Pharmaceuticals Inc Major Business
Table 105. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 106. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 107. Sova Pharmaceuticals Inc Recent Developments/Updates
Table 108. Sova Pharmaceuticals Inc Competitive Strengths & Weaknesses
Table 109. DermaXon LLC Basic Information, Manufacturing Base and Competitors
Table 110. DermaXon LLC Major Business
Table 111. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 112. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 113. DermaXon LLC Recent Developments/Updates
Table 114. DermaXon LLC Competitive Strengths & Weaknesses
Table 115. Kineta Inc Basic Information, Manufacturing Base and Competitors
Table 116. Kineta Inc Major Business
Table 117. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 118. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 119. Kineta Inc Recent Developments/Updates
Table 120. Kineta Inc Competitive Strengths & Weaknesses
Table 121. Krenitsky Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 122. Krenitsky Pharmaceuticals Inc Major Business
Table 123. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 124. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 125. Krenitsky Pharmaceuticals Inc Recent Developments/Updates
Table 126. Krenitsky Pharmaceuticals Inc Competitive Strengths & Weaknesses
Table 127. PeriphaGen Basic Information, Manufacturing Base and Competitors
Table 128. PeriphaGen Major Business
Table 129. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 130. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 131. PeriphaGen Recent Developments/Updates
Table 132. PeriphaGen Competitive Strengths & Weaknesses
Table 133. Apexian Pharma Basic Information, Manufacturing Base and Competitors
Table 134. Apexian Pharma Major Business
Table 135. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 136. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 137. Apexian Pharma Recent Developments/Updates
Table 138. WinSanTor Basic Information, Manufacturing Base and Competitors
Table 139. WinSanTor Major Business
Table 140. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 141. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 142. Global Key Players of Chemotherapy Induced Peripheral Neuropathy Treatment Upstream (Raw Materials)
Table 143. Chemotherapy Induced Peripheral Neuropathy Treatment Typical Customers
Table 144. Chemotherapy Induced Peripheral Neuropathy Treatment Typical Distributors
List of Figure
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Picture
Figure 2. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value and Forecast (2019-2030) & (USD Million)
Figure 4. World Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030) & (K Units)
Figure 5. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (2019-2030) & (US$/Unit)
Figure 6. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share by Region (2019-2030)
Figure 7. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share by Region (2019-2030)
Figure 8. North America Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030) & (K Units)
Figure 9. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030) & (K Units)
Figure 10. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Production (2019-2030) & (K Units)
Figure 11. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Figure 12. Factors Affecting Demand
Figure 13. World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 14. World Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share by Region (2019-2030)
Figure 15. United States Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 16. China Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 17. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 18. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 19. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 20. ASEAN Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 21. India Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2019-2030) & (K Units)
Figure 22. Producer Shipments of Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2023
Figure 23. Global Four-firm Concentration Ratios (CR4) for Chemotherapy Induced Peripheral Neuropathy Treatment Markets in 2023
Figure 24. Global Four-firm Concentration Ratios (CR8) for Chemotherapy Induced Peripheral Neuropathy Treatment Markets in 2023
Figure 25. United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share Comparison (2019 & 2023 & 2030)
Figure 26. United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share Comparison (2019 & 2023 & 2030)
Figure 27. United States VS China: Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share 2023
Figure 29. China Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share 2023
Figure 30. Rest of World Based Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share 2023
Figure 31. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 32. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share by Type in 2023
Figure 33. Calcium Channel α2-delta Ligands
Figure 34. Antidepressants
Figure 35. Opioids
Figure 36. Others
Figure 37. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share by Type (2019-2030)
Figure 38. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share by Type (2019-2030)
Figure 39. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Type (2019-2030) & (US$/Unit)
Figure 40. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 41. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share by Application in 2023
Figure 42. Platinum Agents
Figure 43. Taxanes
Figure 44. Vinca Alkaloids
Figure 45. Others
Figure 46. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Market Share by Application (2019-2030)
Figure 47. World Chemotherapy Induced Peripheral Neuropathy Treatment Production Value Market Share by Application (2019-2030)
Figure 48. World Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Application (2019-2030) & (US$/Unit)
Figure 49. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain
Figure 50. Chemotherapy Induced Peripheral Neuropathy Treatment Procurement Model
Figure 51. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Model
Figure 52. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Aptinyx Inc Asahi Kasei Pharma Corp Regenacy Pharmaceuticals MAKScientific LLC Metys Pharmaceuticals AG Nemus Bioscience Inc PledPharma Sova Pharmaceuticals Inc DermaXon LLC Kineta Inc Krenitsky Pharmaceuticals Inc PeriphaGen Apexian Pharma WinSanTor
Related Reports
23 Mar 2021
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
